trending Market Intelligence /marketintelligence/en/news-insights/trending/hQoOtmu6bsu6h0BKyT6PRw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

BridgeBio abandons bid to acquire remaining stake in Eidos Therapeutics

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

BridgeBio abandons bid to acquire remaining stake in Eidos Therapeutics

BridgeBio Pharma Inc. terminated its bid for the remaining stake in Eidos Therapeutics Inc. as it failed to reach an agreement with a special committee of Eidos' board.

Palo Alto, Calif.-based BridgeBio, which develops therapies for genetic diseases, owns about 66% stake in Eidos. The company's final offer was equivalent to 1.5 BridgeBio shares for each Eidos share.

Initially, BridgeBio offered 1.3 shares for each Eidos share. A special committee of Eidos board unanimously rejected the offer in September.

Under the offer, Eidos' shareholders had the option to choose between receiving their consideration as all-stock, cash and stock mix, or all-cash, such that the transaction is not more than $110 million.

San Francisco-based biotechnology company Eidos develops treatments for a progressive condition associated with the buildup of abnormal deposits of a certain protein called amyloid in the organs and tissues.

Eidos' stock price was down 6.7% to $36.01 as of 1:43 p.m. on Oct. 14.